CURRICULUM VITAE JOHANNES J.P. KASTELEIN Amsterdam, September 2020 Short biography of John J.P. Kastelein, MD PhD FESC Dr. Kastelein (1954) is Emeritus Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he held the Strategic Chair of Genetics of Cardiovascular Disease. Professor Kastelein has published over 1320 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA and Circulation and has a Hirsch index of 122 in January 2020. His citations reached over 680 in 2020 and in total over 74800. Source: Web of Science John J.P. Kastelein is currently the CSO of New Amsterdam Pharma, a company developing Obicetrapib, a CETP inhibitor,that lowers LDL-cholesterol ands apoB and reduces CV risk . He is also the acting chief medical officer (CMO) of Statin Biotechnology Inc., a company developing a monoclonal antibody (Mab) against apolipoprotein CIII and he holds a Board position in North Sea Therapeutics, a company involved in NASH and cardiometabolic therapeutics. Dr. Kastelein is chief executive officer (CEO) of the Vascular Resesarch Network (VRN), a site maintenance organization comprising over 50 hospitals in the Netherlands, involved in clinical trials for cardiometabolic disease. Next to these functions, Dr. Kastelein is key advisor to a number of biotech and pharmaceutical companies. For a comprehensive list, see below. He received his medical degree in Amsterdam in 1980 where he subsequently received specialty training in internal medicine. Then, between 1986 and 1988, he was trained in medical genetics, lipidology and molecular biology at the University of British Columbia, Vancouver under the guidance of Prof. Dr. M.R. Hayden. In 1997 and 1998 he served a visiting Professorship at the Center for Molecular Medicine and Therapeutics at the University of British Columbia, Vancouver, Canada. Upon his return to the Netherlands, he was awarded a doctorate (Cum Laude) and in 1989 he founded the Lipid Research Clinic at the Academic Medical Center, AMC) in Amsterdam, which is currently serving as a tertiary referral centre and has become part of the department of Vascular Medicine of the University of Amsterdam. An important concept in Dr. Kastelein’s research career, developed initially at the University of British Columbia, by his mentor Dr. Hayden, and subsequently transformed into practice at the AMC in Amsterdam, the Netherlands, is the “extreme genetics” approach. This approach teaches that the study of rare human disorders that are associated with premature coronary disease have broader relevance for the understanding of the etiology of heart disease in general and will yield therapeutic targets that are valid for all patients. This approach has been very successful, in so far that Familial Hypercholesterolemia is now internationally recognized as the paradigm for the relationship between LDL-C and heart disease, a relationship substantiated by at least 50 peer reviewed manuscripts and 10 postdoctoral theses in Dr. Kastelein’s curriculum vitae. The same “extreme genetics” concept was applied to disorders of HDL-C and elevated triglycerides and lead to the discovery of the cholesterol efflux protein ABCA1 and later to gene therapy for lipoprotein lipase deficiency. These two innovative contributions to science have lead to important breakthroughs in the field of drug development for the prevention of cardiovascular disease (development of ABCA1 agonists) and in the area of gene therapy for hereditary disorders such as LPL deficiency, haemophilia, LCAT deficiency, homozygous familial hypercholesterolemia and others. In 1995, Dr. Kastelein was one of the initiators of a foundation for the active identification of patients with classical familial hypercholesterolaemia (FH) in the Netherlands (StoeH). This program has now been fully institutionalized and is operational under supervision of the RijksInstituut voor Volksgezondheid en Milieu (RIVM) and financially supported by the Ministry of Health with a total grant of approximately 30 million Euros. Since its inception, the StoeH has found over 25.000 individuals for whom a molecular diagnosis of FH could be made. The subsequent improvement of the treatment of these FH patients has saved many lives, as published in Lancet in 2001 and in the British Medical Journal in 2008. Dr. Kastelein was president of the Dutch Atherosclerosis Society (DAS) and chaired the National Scientific Committee on Familial Hypercholesterolemia (EHC). He also is a member of the Royal Dutch Society for Medicine & Physics, the Council for Basic Science of the American Heart Association and the European Atherosclerosis Society and a Fellow of the European Society of Cardiology. He also is a boardmember of the International Task Force for CHD Prevention and was recently appointed to the Executive Board of the International Atherosclerosis Society (IAS) and is a recognized world leader in the significance of lipoprotein metabolism for the development of atherosclerotic vascular disease. Dr. Kastelein was a principal investigator of the Bloodomics and CardioGenics consortia, two large European Union supported endavours under the Framework Programme 7, that aim to elucidate the molecular basis of atherosclerosis and premature coronary disease. Besides the scientific programmes aimed at the etiology of atherogenesis, Dr. Kastelein also served on a number of executive and steering committees of large cardiovascular intervention studies, including the AEGIS II, CLEAR OUTCOMES, STRENGTH, HORIZON, SPIRE, ORION, GLAGOV, REALIZE, IDEAL, TNT, CAPTIVATE, ENHANCE, ILLUMINATE, JUPITER, RADIANCE and numerous others of which TNT (2005), RADIANCE 1 (2007), ENHANCE (2008), JUPITER (2008), SPIRE and ORION (2017) are published in the New England Journal of Medicine, IDEAL (2006) and GLAGOV (2017) in JAMA and RADIANCE 2 (2007) , TULIP(2015) and REALIZE (2016) in Lancet. Dr. Kastelein is invited regularly to important meetings on vascular disease for invited or keynote lectures, at least 5 meetings per year (American Heart Association, American College of Cardiology, European Society of Cardiology, International Atherosclerosis Society, European Atherosclerosis Society, European Lipoprotein Conference). Overall, his invited lectures can be numbered in the hundreds. Dr. Kastelein was in 1997 a co-founder of Xenon Genetics Inc., a drug discovery company that has now changed its name into Xenon Pharmaceuticals Inc., listed on the Nasdaq, and is based in Vancouver, Canada. Professor Kastelein was also one of the founders of Amsterdam Molecular Therapeutics Inc. (AMT), a gene therapy company based on the concept of gene replacement in hereditary lipoprotein disorders. AMT has enjoyed a successful Initial Public Offering (IPO) at EuroNext in Amsterdam in the summer of 2007. The results of the first successful human gene therapy trial were widely publicized in the media and are published in ATVB in 2008. Furthermore, this gene therapy (Glybera) has now been approved by the European commission and constitutes the first approved gene therapy worldwide. Amsterdam Molecular Therapeutics has now changed its name into UniQure, listed on the Nasdaq. The review article on the history of Glybera as published in Human Gene Therapy in 2013 belonged to the 10 most cited manuscripts in this journal. In addition, Prof. Kastelein also founded Dezima Inc, a pharmaceutical company that develops assets for the treatment of dyslipidemia and has developed a cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (formerly TA-8995), inlicensed from Mitsubishi Tanabe Pharma Corporation (MTPC). Dezima Pharma was acquired by Amgen in 2015 in one of the largest private equity deals in the biotechnology history of the Netherlands. Dr. Kastelein is currently also involved in a number of other companies, such as Staten Biotech Inc.,North Sea Therapeutics Inc. , Oxitope and Omeicos, all portiofolio companies of Forbion Capital Management, a Dutch venture capital firm. In late 2019, Dr. Kastelein was a founder of New Amsterdam Pharma and currently holds the position of CSO in that company. Since a number of years, Dr. Kastelein is extending his reach into the NAFLD/NASH field. He is the executive advisor to Madrigal Pharmaceuticals for MGL-3196, a consultant to 89Bio and is a Board Member and advisor to North Sea Therapeutics Inc. for Icosabutate, all companies focusing on developing compounds against NAFLD/NASH Last, Dr. Kastelein received the first Lifetime Achievement Award of the Dutch Heart Foundation in 2010 as well as the ZonMW Parel price and has received the Anitschkov Price from the European Atherosclerosis Society for the best atherosclerosis research in Europe in June 2014. In 2014, Dr. Kastelein was also awarded the No.1 position among the Top Worldwide Expers in Hyperlipidemia Research and Treatment by Expertscape. He also was a recipient of the Huibregtsenprice 2014 for the best academic researcher in the Netherlands. He is listed on the worldwide list of the 400 most influential biomedical researchers, Eur J. Clin Invest 2013; 43: 1339-1365. Last, Thomson Reuters has ranked Dr. Kastelein among the top 1% of researchers for the most cited documents in his field and top 100 of the most influential clinical researchers globally in 2015. BIOGRAPHY Name: Kastelein, Johannes Jacob Pieter Place of birth: Haarlemmermeer, the Netherlands Date of birth: 13 January, 1954 Nationality: Dutch EDUCATION 1980 University of Amsterdam Medical Degree 1980 1982 Resident Internal Medicine Military Hospital Dr. A. Matthijsen, Utrecht 1982 Chief Resident, Haemodialysis Unit, Military Hospital Dr. A. Matthijsen, Utrecht 1982 1985 Resident, Internal Medicine, Slotervaart Training Hospital, Amsterdam 1983-1985 Postgraduate Courses and Exams: Haemostasis and Thrombosis Clinical Pharmacology Epidemiology and Biostatistics Immunology Respiration and Circulation 1985 Boerhaave Courses: Renovascular Hypertension Left Ventricular Hypertrophy Electrocardiography 1985 Medical Council of Physicians and Surgeons, Canada Evaluation Examination for Canadian Medical Degree, Paris, France 1985 1986 Resident, Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam 1986 1987 Research Fellow, Department of Laboratory Medicine, University of British Columbia, Vancouver 1987 Clinical Fellow, Department of Medical Genetics, University of British Columbia, Vancouver 1987 1988 Junior Scientist, Lipidologist, Lipid Research Clinic, University of British Columbia, Vancouver 1988 Registration as a Medical Specialist 1989 Young Scientist Award. International Society for Thrombosis and Haemostasis, XIIth Congress, Tokyo, Japan, 1991 Academic Thesis The Molecular Basis of Inherited Disorders of Lipoprotein Metabolism (with honours) 1997 - 1998 Visiting Professor, University of British Columbia, Dept. Of Medical Genetics, Vancouver, Canada. 1999 Co-Chairman Department of Vascular Medicine, Academic Medical Center, University of Amsterdam 2000 Established Investigator Netherlands Heart Foundation 2002 Professor of Medicine; Strategic Chair of Cardiovascular Genetics, University of Amsterdam 2003 Chairman Department of Vascular Medicine, Academic Medical Center, University of Amsterdam 2010 Life Time Achievement Award, Netherlands Heart Foundation 2015 Chairman and Organizer of the International Atherosclerosis Society Meeting in Amsterdam, the Netherlands 2019 Operating partner, Forbion Captial Management CEO, Vascular Research Network B.V. Acting CMO, Staten Biotech Inc. CSO, Dezima Pharma Inc. FUNCTIONS • Operating Partner, Forbion Captial Management • Emeritus Professor of Medicine, Academic Medical Center, University of Amsterdam. • Executive Board, International Atherosclerosis Society • Founder Dezima Pharmaceuticals Inc. • Co-founder, Xenon Pharmaceuticals Inc. • Co-founder, UniQure (formerly Amsterdam Molecular Therapeutics Inc.) • Board, Dutch Atherosclerosis Society • Acting CMO, Staten Biotech Inc. • CSO, Dezima Pharma • CEO, Vascular Research Network MEMBERSHIPS • Dutch Atherosclerosis Society • Dutch Lipoprotein Club • Royal Society for Medicine and Physics, Amsterdam • Council for Basic Science of the American Heart Association • International Atherosclerosis Society • European Society of Cardiology • Steering Committee TNT trial • Steering Committee IDEAL trial • Steering Committee METEOR trial • Steering Committee DISCOVERY trial • Steering Committee ENHANCE trial • Steering Committee RADIANCE I and II trial • Steering Committee ILLUMINATE trial • Steering Committee JUPITER trial • Steering Committee ACHIEVE trial • Steering Committee AQUARIUS trial • Steering Committee CHARON trial • Steering Committee SAVOR trial • Steering Committee MARINE trial • Steering Committee AKKA trial • Steering Committee CANTOS trial • Steering Committee ACCELERATE trial • Steering Committee ODYSSEY programme • Steering Committee REALIZE study • Steering Committee GLAGOV study • Steering Committee EUCLID study • Steering Committee phase II programme Eli Lilly PCSK9 monoclonal • Steering Committee Novartis DGAT inhibitor programme • Steering Committee PASCAL studies • Steering Committee STRENGTH study • Steering Committee AEGIS-1 study • Steering Committee EVOLVE-II study • Steering Committee SPIRE trial programme • Steering Committee CLEAR OUTCOMES trial • Steering Committee AEGIS-II trial • Steering Committee HYDRA study • Steering Committee ORION I and IV trials • Steering Committee CARAT study • Steering Committee phase III programme Eli Lilly PCSK9 monoclonal CONSULTANCIES • 89Bio • Amgen Inc. • AstraZeneca Inc. / MedImmune • Civi Therapeutics • Corvidia Inc. • CSL Behring • Draupnir Bio • Esperion Pharmaceuticals • Gemphire Therapeutics • Madrigal Therapeutics • Matinas Biopharma • Novartis Pharmaceutics • Novo Nordisk • Omeicos • Pfizer Inc. • Regeneron Pharmaceuticals • RegenXBio • Sanofi Aventis • Serometrix • Sirnaomics • TTXD PhD PROJECTS PRESENT Drs. I.K. Luirink FH in children PhD PROJECTS PAST Dr.Ir. J.C. Defesche The molecular basis and treatment of familial hypercholesterolemia 29 January 1993 Dr. P.J. Lansberg The molecular basis and treatment of familial hypercholesterolemia 29 January 1993 Dr. T. Bruin Human Lipoprotein lipase; molecular genetics & structure function analysis. 9 March 1994 (with honours) Dr. H.C. Knipscheer The pharmacological treatment of primary hyperlipidemia. 21 December 1994 Dr. S.M. Bijvoet The molecular biology of familial chylomicronemia. 21 December 1994 Dr. Y.Y. van der Hoek Lipoprotein(a): structure/function analysis and metabolism. 7 September 1995 Dr. J.A. Kuivenhoven Genetic factors contributing to HDL cholesterol levels. 3 December 1996 Dr. B.E. Groenemeijer Genetic factors contributing to dyslipidemia and coronary artery disease. 3 June 1997 Dr. M.E. Wittekoek Familial Hypercholesterolemia. Molecular genetics and clinical expression. 4 December 1998 Dr. S.N. Pimstone Genetic and environmental determinants of dyslipidemia and coronary artery disease. 17 December 1998 Mr. Dr. M.J. Van Dam Dyslipidemia, diagnosis and treatment. 26 October 2001 Dr. M.A.W. Umans-Eckenhausen Genetic insights, clinical efficacy and practical implications of genetic screening for Familial Hypercholesterolemia. 28 November 2002 Dr. P.R.W. de Sauvage Nolting Genetics and therapy of familial hypercholesterolemia. 11 December 2002 Dr. S de Jongh Familial Hypercholesterolemia in childhood. 13 December 2002 Dr. M.D. Trip The spectrum of premature atherosclerosis: from single gene to complex genetic disorder. 19 December 2002 Dr. S. van Wissen Aggressive lipid lowering in patients with familial hypercholesterolaemia. 6 March 2003 Dr. A. Wiegman Pediatric implications of heterozygous Familial Hypercholesterolaemia. 1 July 2003 Dr. R. Singaraja The role of abca1 in atherosclerosis: lessons from in vitro and in vivo models 17 September 2003 Dr. G.J. de Grooth Cholesteryl Ester Transfer Protein. Its role in cardiovascular disease and drug development. 2 December 2003 Dr. A. Jansen Familial hypercholesterolemia. The determination of phenotype 9 December 2003 Dr. J.I. Rotmans Therapeutic Strategies to Prevent Stenosis in Arteriovenous Grafts for Hemodialysis 27 January 2005 Dr. E.S. van Aalst-Cohen Diagnostic criteria and risk factors for cardiovascular disease in familial hypercholesterolemia. 15 March 2005 Dr. S.M. Boekholdt Genetic and biochemical risk factors in coronary artery disease. 15 March 2005 (with honours) Dr. G.K. Hovingh Molecular defects in the metabolism of the HDL particle and the consequences for atherosclerosis progression. 15 April 2005 Dr. S.W. Fouchier Genetic determinants of cholesterol homeostasis. 15 April 2005 Dr. J. Rodenburg Familial Hypercholesterolemia in Childhood: Diagnostics, Therapeuticall Options and Risk Stratification. 13 September 2005 Dr. J.S. Rana The Cardiovascular Metabolic Syndrome 19 October 2005 Dr. J. Rip Lipoprotein Lipase, Hypertriclyceridemie and Atherosclerosis 15 September 2006 Dr. R.J. Bisoendial High-density lipoprotein and C-reactive protein, friend and foe in cardiovascular disease 12 December 2006 Dr. M.C. Nierman Lipoprotein Lipase S447X; from beneficial gene variant to gene therapy 13 December 2006 Dr. R.C. Özsoy The dyslipidemia of chronic renal failure and the effects of statin therapy 15 May 2007 Dr. M. Nieuwdorp Metabolic and vascular dysfunction during hyperglycemia induced inflammation. The role of the endothelial Glycocalyx on vascular homeostatis in vivo 7 September 2007 Dr. K.C.M.C. Koeijvoets Complex genetics of monogenic familial hypercholesterolemia 12 September 2007 Dr. R.S. Birjmohun HDL on the crossroads of inflammation, coagulation and atherosclerosis 28 Mei 2008 Dr. M.C. Meuwese Targetting the vessel wall in cardiovascular prevention. 10 September 2008 Dr. R.R. Sankatsing Atherosclerosis in the HIV and non-HIV setting: detecting and modifying cardiovascular risk 19 November 2008 Dr. W.A. van der Steeg Improving Cardiovascular Disease Prevention: From Risk Assessment to Novel Therapy 6 February 2009 Dr. S.I. van Leuven Inflammation and its Echo in Atherosclerosis 23 June 2009 Dr. S.F.C. Vaessen Apolipoproteins A-I and A-V as gene therapeutic targets to intervene in lipid metabolism 17 September 2009 Dr. A. El Harchaoui The Puzzle of High-Density Lipoprotein in Cardiovascular Prevention 3 December 2009 Dr. F. Akdim LDL-Cholesterol lowering beyond statins 29 April 2010 Dr. R. Franssen Abnormalities in lipoprotein metabolism: from dysfunctional HDL to abnormal processing of triglyceride-rich lipoproteins 26 October 2010 Dr. A. van der Graaf Familial Hypercholesterolemia: Cardiovascular Disease Prevention from Childhood into Adolescents 28 October 2010 Dr. A.M.H. Vergeer HDL Genes and HDL Drugs 10 June 2011 (with honours) Dr. A.G. Holleboom Genetic Disorders of HDL Metabolism: from model to mechanism 17 June 2011 Dr. A.Q. Reuwer Prolactin and Vascular Disease; a first cautious assessment 20 september 2011 Dr. L.N. Broekhuizen Glycocalyx, Cardiometabolic disease and Inflammation 23 september 2011 Dr. S. Sivapalaratnam The molecular basis of early onset cardiovascular disease. 14 september 2012 Dr. B.M. Sondermeijer Cardiovascular Metabolism 19 oktober 2012 Dr. R. Huijgen Familial Hypercholesterolemia: The Dutch Approach 20 december 2012 Dr. R. Duivenvoorden Innovative Imaging Techniques for improved characterization of atherosclerosis and the assessment of novel therapies. 5 september 2013 (with honours) Dr. H.J. Avis Childhood initiated statin therapy in familial hypercholesterolemia. 10 september 2013 Dr. Steffi Maiwald Rare genetic variants associated with early onset CVD 3 maart 2015 Dr. Marjet Braamskamp Management of Pediatric Familial Hypercholesterolemia; growing older, getting wiser 9 december 2015 Dr. Meeike Kusters Familial hypercholesterolemia: screening, treatment and follow-up from pregnancy into young adulthood 23 februari 2016 Dr. Joost Besseling The extended phenotype of familial hypercholesterolemia. 7 oktober 2016 Dr. Barbara Sjouke Extreme phenotypes in hypercholesterolemia: from genotype to therapy. 1 februari 2017 PUBLICATIONS 1983 1. Het koerierssyndroom. J. Geerling, J.J.P. Kastelein, D. Agenant. Ned. Tijdschr. Geneeskd. 1983; 127: 874 64. 1985 2. Urinary creatine: Biochemical indicator for evaluation of sickle cell crises. C. Beyer, L.W. Statius van Eps, J.J.P. Kastelein, D.P.M. Brandjes, W.M. Mairuhu, A. van den Ende. Clin. Chem. 1985; 31; 1232 1234. 1986 3. First trimester prenatal diagnosis for Huntington disease using DNA probes. M.R. Hayden, J.J.P. Kastelein, J. Hewitt, S. Langlois, R.D. Wilson, S. Fox, C.M. Hilbert, M. Bloch. Lancet 1987; I: 1284 85. 4. Insufficient evidence to invoke defects in or around the AI gene as the cause for familial hypoalphalipoproteinemia. M.R. Hayden, J.J.P. Kastelein, S. Langlois. Atherosclerosis 1987; 67: 271 72. 1988 5. A polymorphic DNA marker which represents a conserved expressed sequence in the region of the Huntington Disease gene. M.R. Hayden, J. Hewitt, J.J. Wasmutn, J.J.P. Kastelein, J. Haines, B. Smith, M. Conneally, C.M. Hilbert, S. Allard. Am. J. Hum. Genet. 1988; 42: 125 31. 6. Characterization of six partial deletions in the low density lipoprotein (LDL) receptor gene causing familial hypercholesterolemia (FH). S. Langlois, J.J.P. Kastelein, M.R. Hayden. Am. J. Hum. Genet. 1988; 43: 60 68. 1989 7. A major insertion accounts for a significant proportion of mutations underlying human lipoprotein lipase deficiency. S. Langlois, S. Deeb, J.J.P. Kastelein, J.D. Brunzell, M.R. Hayden. Proc. Natl. Acad. Sci. USA 1989;86:948 952. 8. Niertubulusfunctiestoornissen door azijnzuur. G.H.C. Schardijn, J.J.P. Kastelein, L.W. Statius van Eps. Ned. Tijdschr. Geneeskd. 1989;133:556-558. 1990 9. The gene causing familial hypoalphalipoprotenemia is not caused by a defect in the Apo AI CIII AIV gene cluster in a Spanish family. J.J.P. Kastelein, J.L. Haines, M.R. Hayden. Human. Genet. 1990; 84: 396 400. 10. A missense mutation at codon 188 of the human lipoprotein lipase gene causes lipoprotein lipase deficiency in persons of different ancestries. M.V. Monsalve, H. Henderson, G. Roederer, P. Julien, S. Deeb, J.J.P. Kastelein, L. Peritz, R. Devlin, T. Bruin, M.R.V. Murthy, C. Gagne. J.D. Brunzell, M.R. Hayden. J. Clin. Invest. 1990;86:728-734 1991 11. The prediction of the therapeutic response to cholesterol lowering drugs in an 11 year old boy with homozygous familial hypercholesterolemia. H.D. Bakker, P.P.M. Schilte, T. Bruin, M.C.L. Schaap, P.J. Lansberg and J.J.P. Kastelein. J. Inher. Metab. Dis. 1991:14;3. 12. De Low Density Lipoprotein (LDL) receptor. Caput Selectum. J.J.P. Kastelein, J.W. ten Cate. Ned. Tijdschr. Geneeskd. 1991;135:646-651. 13. High-Density Lipoproteine. J.J.P. Kastelein. Ned. Tijdschr. Klin. Chem. 1991;16:106-109. 14. Een patient met de homozygote vorm van Familiaire Hypercholesterolemie. J.W. Gorter, J.J.P. Kastelein, P.J. Lansberg, P.P.M. Schilte, H.D. Bakker. Ned. Tijdschr. Kindergeneesk. 1991;59:88-91. 15. The molecular defect causing fish eye disease: An amino acid exchange in lecithin: cholesterol acyltransferase (LCAT) leads to the selective loss of alpha LCAT activity. H. Funke, A. von Eckardstein, P.H. Pritchard, J.J.P. Kastelein, J.J. Albers, C.C. Droste, G. Assmann. Proc. Natl. Acad. Sci. (USA) 1991;88:4855-4859. 16. HindIII-polymorphism in the LPL-gene detected by PCR. T. Bruin, P.W.A. Reymer, B.E. Groenemeyer, P.J. Talmud and J.J.P. Kastelein. Nucl. Acids. Res 1991;19:6346. 1992 17. Hemostase, Thrombose en Perifere Vaatziekten. A. Sturk, H.R. Büller, J.J.P. Kastelein, J.W. ten Cate. Hoofdstuk in Leerboek Interne Geneeskunde 1992, Eds. G.J. den Ottolander. 10e herziene druk. Bohn, Stafleu, van Loghum, Houten/Zeventer. 18. Two naturally occuring mutations at the first and second base of codon Asp156 in the proposed catalytic triad of human lipoprotein lipase - in vivo evidence that Asp156 is essential for catalysis. Y. Ma, S. Tuzgöl, T. Bruin, J.D. Brunzell, J.J.P. Kastelein and M.R. Hayden. J. Biol. Chem. 1992;267(3):1918-1923 19. Lipoproteine Lipase. Caput Selectum. J.J.P. Kastelein, T. Bruin, J.W. ten Cate. Ned. Tijdschr. Geneesk. 1992;15:727-730 20. High Density Lipoproteine. Caput Selectum. J.J.P. Kastelein, R.P.G. Peters en J.W. ten Cate. Ned. Tijdschr. Geneeskd. 1992;136:723-726 21. De behandeling van Familiaire Hypercholesterolemie. Caput Selectum. P.J. Lansberg, J.J.P. Kastelein, J.C. Defesche en J.W. ten Cate. Ned. Tijdschr. Geneeskd. 1992;136:734-738 22. Familial high-density lipoprotein deficiency causing corneal opacities (fish eye disease) in a family of Dutch descent. J.J.P. Kastelein, P.H. Pritchard, D.W. Erkelens, J.J. Albers, J.J. Frohlich. J. Int. Med. 1992;231:413-419 23. Postmenopausale oestrogeen substitutie en het risico voor atherosclerotische hart- en vaatziekten. Caput Selectum. Commentaar. E. Dekker, H.R. Büller and J.J.P. Kastelein. Ned. Tijdschr. Geneeskd. 1992;25:1197-1200. 24. A missense mutation (Asp250Asn) in exon 6 of the human lipoprotein lipase gene causes hyperchylomicronemia in patients of different ancestries. Y. Ma, B.I. Wilson, S. Bijvoet, H.E. Henderson, E. Cramb, G. Roederer, M.R. McMurthy, P. Julien, H. Bakker, J.J.P. Kastelein, J.D. Brunzell, M.R. Hayden. Genomics. 1992;13:649-653. 25. Absence of mutations in the promoter region of the low density lipoprotein receptor gene in a large number of Familial Hypercholesterolemia patients as revealed by denaturing gradient gel electrophoresis. B. Top, A.G. Uiterlinden, A. v.d. Zee, J.J.P. Kastelein, J.A. Gevers Leuven, L.M. Havekes and R.R. Frants. Hum. Genet. 1992;89:561-565. 26. The familial hyperchylomicronaemia syndrome. S.M. Bijvoet, T. Bruin, J.J.P. Kastelein. Neth. J. Med. 1992;42:36-44. 27. Molecular Geography of Inherited Disorders of Lipoprotein Metabolism: Lipoprotein Lipase Deficiency and Familial Hypercholesterolemia. Hayden M.R., De Braekeleer M., Henderson H.E., and Kastelein J.J.P. Chapter in: Genetic Factors in Atherosclerosis-Candidate Genes and Processes. Eds. A.J. Lusis, J.I. Rotter and R.S. Sparkes. Monogr. Hum. Genet. Basel, Karger 1992;14:350-362. 28. A missense mutation (Pro157  Arg) in lipoprotein lipase (LPLnijmegen) resulting in loss of catalytic activity. T. Bruin, J.J.P. Kastelein, D.E. van Diermen, Y. Ma, H.E. Henderson, P.M.J. Stuyt, A.F.H. Stalenhoef, A. Sturk, J.D. Brunzell, M.R. Hayden. Eur. J. Biochem. 1992;208:267-272. 29. Detection of the Pro664  Leu mutation in the low-density lipoprotein-receptor gene and its relation to lipoprotein(a) levels in patients with familial hypercholesterolemia of Dutch ancestry from the Netherlands and Canada. J.C. Defesche, M.A. van de Ree, J.J.P. Kastelein, D.E. van Diermen, N.W.E. Janssens, J.J. van Doormaal and M.R. Hayden. Clin. Genet. 1992;42:273-280. 30. Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (a multicenter comparative study). The European Study group. Am. J. Cardiol. 1992;70:1281-1286. 1993 31. Analysis of the Afrikaner mutation in exon 9 of the low-density lipoprotein receptor gene in a large Dutch kindred suffering from Familial Hypercholesterolemia. J.C. Defesche, P.J. Lansberg, P.W. Reymer, R.J. Lamping, J.J.P. Kastelein. Neth. J. Med. 1993; 42: 53-60. 32. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Y.Y. van der Hoek. M.E. Wittekoek, U. Beisiegel, J.J.P. Kastelein and M.L. Koschinsky. Hum. Mol. Genet., 1993; 2(4): 361-366. 33. Comparison of the efficacy, safety and tolerability of Simvastatin and Pravastatin for Hypercholesterolemia. The Simvastatin Pravastatin Study Group. Am. J. Cardiol. 1993; 71: 1408-1414. 34. Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study. A.F.H. Stalenhoef, P.J. Lansberg, A.A. Kroon, B. Kortmann, A.F.J. de Haan, P.M.J. Stuyt and J.J.P. Kastelein. J. Intern. Med. 1993; 234; 77-82. 35. The identification of familial hypercholesterolemia in The Netherlands. J.J.P. Kastelein. Can. J. Cardiol. 1993; 9(suppl. d): 100D-101D. 36. Recurrent pancreatitis and chylomicronemia in an extended Dutch kindred is caused by a Gly154Ser substitution in lipoprotein lipase. T. Bruin, S. Tuzgöl, D.E. van Diermen, N. Hoogerbrugge-v.d. Linden, J.D. Brunzell, M.R. Hayden, J.J.P. Kastelein. J. Lipid Res. 1993; 34: 2109-2119. 37. Structure-function relationships of lipoprotein lipase: mutation analysis and mutagenesis of the loop region. H.E. Henderson, Y. Ma, M-S. Liu, I. Clark-Lewis, D.L. Maeder, J.J.P. Kastelein, J.D. Brunzell, M.R. Hayden. J. Lipid Res. 1993; 34: 1593-1602. 38. South African founder mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia in the Dutch population. J.C. Defesche, D.E. van Diermen, P.J. Lansberg, R.J. Lamping, P.W.A. Reymer, M.R. Hayden, J.J.P. Kastelein. Hum. Genet. 1993; 92: 567-570. 39. Familial Defective Apolipoprotein B100 is clinically indistinguishable from Familial Hypercholesterolemia. J.C. Defesche, K.L. Pricker, M.R. Hayden, A.E. v.d. Ende, J.J.P. Kastelein. Arch. Int. Med. 1993; 153: 2349-2356. 1994 40. Phenotypic variation of mutations in the human lipoprotein lipase gene. M.R. Hayden, J.J.P. Kastelein. H. Funke, J.D. Brunzell, Y. Ma. Biochemical Society Trans. 1994; 21: 506-509. 41. Recurrent missense mutations at the first and second base of Codon Arg243 in human lipoprotein lipase in patients of different ancestries. Y. Ma, M.S. Liu, D. Chitayat, T. Bruin, U. Beisiegel, P. Benlian, L. Foubert, J.L. de Gennes, H. Funke, I. Forsythe, S. Blaichman, M. Papanikolaou, D.W. Erkelens, J.J.P. Kastelein, J.D. Brunzell, M.R. Hayden. Human Mutation. 1994; 3: 52-58. 42. Atherosclerose mede veroorzaakt door lokale vaatontsteking. S.J.H. van Deventer, J. Kastelein en J.W. ten Cate. Ned. Tijdschr. Geneesk 1994;138:443-8. 43. A compound heterozygote for lipoprotein lipase-deficiency: Val69Leu and Gly188Glu: correlation between in vitro LPL activity and clinical expression. T. Bruin, S. Tuzgol, W.J. Mulder, A.E. van den Ende, H. Jansen, M.R. Hayden and J.J.P. Kastelein. J. Lipid Res. 1994; 35: 438-445. 44. Homozygosity for a mutation in the lipoprotein lipase gene (Gly139Ser) causes chylomicronemia in a boy of Spanish descent. S.M. Bijvoet, T. Bruin, S. Tuzgöl, H.D. Bakker, M.R. Hayden, J.J.P. Kastelein. Hum. Genet. 1994; 93: 339- 45. Screening for Familial Defective apolipoprotein B-100 with improved U937 monocyte proliferation assay. A.J.C.M. v.d. Broek, L. Hollaar, H.I.M.B. Schaefer, A. v.d. Laarse, H. Schuster, J.C. Defesche, J.J.P. Kastelein, F.M. van 't Hooft. Clin. Chim. 1994; 40(3): 395-399. 46. Decreased resistance against in vitro oxidation of low density lipoproteins from patients with familial defective apolipoprotein B100. A. Stalenhoef, J. Defesche, H. Kleinveld, P. Demacker, J.J.P. Kastelein. Arterioscl. Thromb 1994;14:489-493. 47. The C-terminus of lipoprotein lipase is essential for biological function but contains no domain for glycosylphosphatidylinositol anchoring. T. Bruin, N.B. Groot, J. Jansen, J.J.P. Kastelein. Eur. J. Biochem. 1994; 221: 1019-1025. 48. Analysis of structure-function relationships in human apolipoprotein(a). Y.Y. van der Hoek, J.J.P. Kastelein, M.L. Koschinsky. Can. J. Physiol. Pharmacol. 1994; 72: 304-310. 49. Apolipoprotein CIIPadova (Tyr37Stop) underlying chylomicronemia in an Italian kindred from Sicily. S. Tuzgöl, S.M. Bijvoet, T. Bruin, J.J.P. Kastelein, M.R. Hayden. J. Med. Genet., 1994; 31: 622-626. 50. Gemfibrozil treatment of the high triglyceride-low high density lipoprotein cholesterol trait in men with established atherosclerosis. H.C. Knipscheer, M.T. Nurmohamed, A. van den Nede, B. Plaat, H.J.W. Pruijs, W.J. Mulder, J.J.P. Kastelein. J. Intern. Med. 1994, 236: 377-384. 51. Binding of recombinant apolipoprotein(a) to extracellular matrix proteins. Y.Y. van der Hoek, W. Sangrar, G.P. Côté, J.J.P. Kastelein, M.L. Koschinsky. Arteriosclerosis and Thrombosis, 1994; 14(11): 1792-1798. 52. Familial hypercholesterolemia in Dutch children: past, present and future. H.D. Bakker, L.M.J. Trum, J.C. Defesche, J.J.P. Kastelein. Int. Pediatrics, 1994; 9(3): 157-164. 53. The effect of Fiberform, a low phytate wheat fiber, on plasma lipids and blood pressure in women with Familial Hypercholesterolemia. H.C. Knipscheer, P.J. Lansberg, J.J.P. Kastelein, M. Nurmohamed, M.H. Prins, A.E. van der Ende, J.W. ten Cate. J. Int. Med. 1994; 236: 477-478. 54. The molecular and biochemical diagnosis and the therapy of familial hypercholesterolemia in childhood. H.D. Bakker, A. Wiegman, L. Feuth, J.C. Defesche, J.J.P. Kastelein. In: Current trends on the prevention of atherosclerosis in childhood. Proceedings of the International Congress on Prevention of Atherosclerosis in childhood. October 1994 Budapest, Hungary. Ed. Dr. Tamás Szamosi. 55. Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2(Lys146Gln) allele carriers. P. de Knijff, A.M.J.M. van den Maagdenberg, D.I. Boomsma, A.F.H. Stalenhoef, A.H.M. Smelt, J.J.P. Kastelein, A.D. Marais, R.R. Frants, L.M. Havekes. J. Clin. Invest. 1994; 94: 1252-1262. 1995 56. Mutations in the low density lipoprotein receptor gene of familial hypercholesterolemic patients detected by denaturing gradient gel electrophoresis and direct sequencing. P. Lombardi, E.J.G. Sijbrands, K. van de Giessen, A.H.M. Smelt, J.J.P. Kastelein, R.R. Frants, L.M. Havekes. J. Lipid Res. 1995; 36: 860-867. 57. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. P.W.A. Reymer, E. Gagné, B.E. Groenemeyer, H. Zhang, I.J. Forsyth, H. Jansen, J.C. Seidell, D. Kromhout, K.E. Lie, J.J.P. Kastelein, M.R. Hayden. Nature Genetics, 1995; 10: 28-34. 58. A common variant in the gene for lipoprotein lipase (Asp9Asn). Functional implications and prevalence in normal and hyperlipidaemic subjects. F. Mailly, Y. Tugrul, P.W.A. Reymer, T. Bruin, M. Seed, B.E. Groenemeyer, A. Asplund-Carlson, D. Vallance, A.F. Winder, G.J. Miller, J.J.P. Kastelein, A. Hamsten, G. Olivecrona, S.E. Humphries, Ph.J. Talmud. Arteriosclerosis and Throms, 1995; 15: 468-478. 59. Apolipoprotein-E genotyping on agarose gels. P.W.A. Reymer, B.E. Groenemeyer, R. v.d. Burg, J.J.P. Kastelein. Clin. Chem. 1995; 41: 1046-1047. 60. A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. P.W.A. Reymer, B.E. Groenemeyer, E. Gagné, Li Miao, E.E.G. Appelman, J.C. Seidel, D. Kromhout, S.M. Bijvoet, K. v.d. Oever, T. Bruin, M.R. Hayden, J.J.P. Kastelein. Hum Mol Genet 1995; 4: 1543-1549. 61. Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. M.J.M. Diekman, P.J. Lansberg, J.J.P. Kastelein and W.M. Wiersinga. Arch Intern Med 1995; 155: 1490-1495. 62. Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients. P. Lansberg, Y. Mitchel, D. Shapiro, J. Kastelein, R. Altman, G. Jerums, K. Bolzano, S. Giannini, J. Davignon, P. DeWailly, R. Darioli, M. Mancini, R. Scott, M. Hayden. Atherosclerosis 1995; 116: 153-162. 63. Comparison of Gemfibrozil versus Simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. S. Bredie, T. de Bruin, P. Demacker, J. Kastelein, A. Stalenhoef. Am J Cardil 1995;75:348-3 64. Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolaemia. L. Ose, R. Scott and the Simvastatin-Fluvastatin Study Group. Clin Drug Invest 1995; 10: 127-138. 65. Patients with ApoE3 deficiency (E2/2, E3/2 and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291Ser mutation in the human LPL gene. H. Zhang, P.W.A. Reymer, M.S. Liu, I.J. Forsythe, B.E. Groenemeyer, J. Frohlich, J.D. Brunzell, J.J.P. Kastelein, M.R. Hayden and Y. Ma. Arteriosclerosis and Thrombosis 1995; 15: 1695-1703. 66. Mutations in the gene for lipoprotein lipase: a cause for low HDL cholesterol levels in individuals heterozygous for familial hypercholesterolemia. S.N. Pimstone, E. Gagné, C. Gagné, P.J. Lupien, D. Gaudet, R.R. Williams, M. Kotze, P.W.A. Reymer, J.C. Defesche, J.J.P. Kastelein, S. Moorjani, M.R. Hayden. Arteriosclerosis & Thrombosis 1995; 15: 1704 - 1712. 67. A unique genetic and biochemical presentation of Fish-eye Disease. J.A. Kuivenhoven, E.J.G.M. van Voorst tot Voorst, H. Wiebusch, S.M. Marcovina, H. Funke, G. Assmann, P.H. Pritchard, J.J.P. Kastelein. J Clin Invest 1995; 96: 2783-2791. 1996 68. The lipoprotein lipase (Asn291Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidaemia. M.J.V. Hoffer, S.J.H. Bredie, D.I. Boomsma, P. Reymer, J.J.P. Kastelein, P. de Knijff, P.N.M. Demacker, A.F.H. Stalenhoef, L.M. Havekes, R.R. Frants. Atherosclerosis 1996; 119: 159-167. 69. Two novel molecular defects in the LCAT gene are associated with Fish-eye disease. J.A. Kuivenhoven, A.F.H. Stalenhoef, J.S. Hill, P.N.M. Demacker, A. Errami, J.J.P. Kastelein, P.H. Pritchard. Arterioscler Thromb Vasc Biol. 1996; 16: 294-303. 70. Alterations in plasma lipoproteins and apoproteins before the age of 40 in heterozygotes for LPL deficiency. S.M. Bijvoet, S.E. Gagné, S. Moorjani, C. Gagné, H.E. Henderson, J.C. Fruchart, J. Dallongeville, P. Alaupovic, M. Prins, J.J.P. Kastelein, M.R. Hayden. J Lipid Res 1996; 37: 640-650. 71. Short-term efficacy and safety of Pravastatin in 72 children with familial hypercholesterolemia. H.C. Knipscheer, C.C.A. Boelen, J.J.P. Kastelein, D.E. van Diermen, B.E. Groenemeyer, A.E. van den Ende, H.D. Bakker. Paediatric Res 1996; 39: 867-871. 72. MED PED: an integrated strategy for preventing early deaths. Williams RR, Hamilton-Craig I, Kostner GM, Hegele RA, Hayden MR, Pimstone SN, Faergeman I, Schuster H, Steinhage-Thiessen E, Beisiegel U, Keller C, Czeizel A, Leitersdorf E, Kastelein JJP, Defesche JC, Ose L, Leren T, Seftel HC, Raal FJ, Marais AD, Eriksson M, Keller U, Miserez A, Jeck T, Betteridge DJ, Humphries SE, Day INM, Kwiterovich PO, Lees RS, Stein E, Illingworth R, Kane J and Bouyjenkov V.1996. WHO/Ipsen Foundation/ Springer Verlag Berling. pp. 35-45 73. Compound heterozygosity for a known (D250N) and a novel (E410K) missense mutation in the C-terminal domain of lipoprotein lipase causes familial chylomicronemia. H. Wiebusch, H. Funke, T. Bruin, H. Bucher, A. von Eckardstein, J.J.P. Kastelein and G. Assmann. Hum Mutation 1996; 8: 381-383. 74. Hormone replacement therapy: a useful tool in the prevention of coronary artery disease in postmenopausal women? The working group on women and cardiovascular disease of the Netherlands Heart Foundation. Eur Heart J 1996; 17: 658-666. 75. An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease). J.A. Kuivenhoven, H. Wiebusch, P.H. Pritchard, H. Funke, R. Benne, G. Assmann, J.J.P. Kastelein. J Clin Invest 1996; 98: 358-364. 76. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidemia. H.C. Knipscheer, J.C. de Valois, A. van den Ende, J.W. ten Cate, J.J.P. Kastelein. Atherosclerosis 1996; 124 (suppl.) S75-S81. 77. Origin and migration of an Afrikaner founder mutation FHAfrikaner-2 (V408M) causing familial hypercholesterolemia. J.C. Defesche, D.E. van Diermen, M.R. Hayden, J.J.P. Kastelein. Gene Geography 1996; 10: 1-10. 78. Lipoprotein(a). A. van den Ende, Y.Y. van der Hoek, J.J.P. Kastelein, M.L. Koschinsky, C. Labeur, M. Rosseneu. Adv Clin Chem 1996; 32: 73-134. 79. Compound heterozygosity for a known and a novel defect in the lipoprotein lipase gene (Asp250Asn and Ser251Cys) resulting in lipoprotein lipase (LPL) deficiency. S. Bijvoet, H. Wiebusch, Y. Ma, P. Reymer, T. Bruin, H.D., H. Funke, G. Assmann, M. Hayden and J.J.P. Kastelein. Neth J Med 1996;49:189-195. 80. The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. J.W. Jukema, A.J. van Boven, B.E. Groenemeijer, A.H. Zwinderman, J.H.C. Reiber, A.V.G. Bruschke, J.A. Henneman, G.P. Molhoek, T. Bruin, H. Jansen, E. Gagné, M.R. Hayden, J.J.P. Kastelein; Circulation 1996; 94: 1913-1918. 81. A common alteration in the LPL gene resulting in altered lipoprotein levels. S. Pimstone, E. Gagné, H. Zhang, P.W.A. Reymer, J.J.P. Kastelein, Y. Ma, M.R. Hayden. In: Pennington Center Nutrition Series. Volume 6: Nutrition, genetics and heart disease. G.A. Bray, D.H. Ryan, eds. pp: 258-275. 82. Identification of a double mutation in the low density lipoprotein receptor gene causing familial hypercholesterolemia. P. Lombardi, S.W.A. Kamerling, J.C. Defesche, J.J.P. Kastelein, L.M. Havekes. Clin Genet 1996; 50: 525-526. 83. Modulation of plasma fibrinogen levels by medication. M.P.M. de Maat, M. Kockx, J.J.P. Kastelein, C. Kluft. Fibrinolysis 1996; 10: suppl. 4: 7. 1997 84. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. E.S.G. Stroes, J.J.P. Kastelein, F. Cosentino, D.W. Erkelens, R. Wever, H.A. Koomans, T.F. Lüscher, T.J. Rabelink. J Clin Invest 1997; 99: 41-46. 85. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia. M.P.M. de Maat, H.C. Knipscheer, J.J.P. Kastelein, C. Kluft. Thrombosis & Haemostasis 1997; 77: 75-79. 86. Mutation of tryptophan residues in lipoprotein lipase. Effects on stability, immunoreactivity and catalytic properties. A. Lookene, N.B. Groot, J.J.P. Kastelein, G. Olivecrona and T. Bruin. J Biol Chem 1997; 272: 766-772. 87. The molecular pathology of lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. J.A. Kuivenhoven, H. Pritchard, J. Frohlich, G. Assmann, J.J.P. Kastelein. J Lipid Res 1997; 38: 191-205 88. The Ser447-Stop mutation in lipoprotein lipase is associated with elevated HDL cholesterol levels in normolipidemic males. J.A. Kuivenhoven, B.E. Groenemeijer, J.M.A. Boer, P.W.A. Reymer, R. Berghuis, T. Bruin, H. Jansen, J.C. Seidell, J.J.P. Kastelein. Arterioscler Thromb Vasc Biol 1997; 17: 595-599 89. Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. J. Kuivenhoven, P. de Knijff, J. Boer, H.A. Smalheer, G. Botma, J. Seidell, J.J.P. Kastelein and P. Pritchard. A TVB 1997; 17: 560-568 90. Phenotypic variation in patients heterozygous for familial defective apolipoprotein B (FDB) in three European countries. P.S. Hansen, J.J.P. Kastelein, L.U. Gerdes, L. Fraza, C. Gerdes, F. Tato, H.K. Jensen, L.G. Jensen, I.C. Klausen, O. Faergeman, H. Schuster. ATV Biol 1997; 17: 741-747. 91. Magnesium-pyridoxal-5-phosphate glutamate “A vitamin B6 derivative”, does not affect lipoprotein levels in patients with familial hypercholesterolemia. H.C. Knipscheer, I. Kindt, A.E. van den Ende, M.T. Nurmohamed, H. Smalbraak, W.J. Mulder, J.J.P. Kastelein. Eur J Clin Pharmacol 1997; 51: 499-503. 92. Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia. S.N. Pimstone, J.C. Defesche, S.M. Clee, H.D. Bakker, M.R. Hayden, J.J.P. Kastelein. Arterioscler Thromb Vasc Biol 1997; 17: 826-832. 93. Short report on DNA marker at candidate locus. A novel V415A mutation in exon 9 of the low density lipoprotein receptor gene causing familial hypercholesterolemia. P. Lombardi, J.C. Defesche, S.W.A. Kamerling, J.J.P. Kastelein, L.M. Havekes. Clin Genet 1997; 51: 286-287. 94. Sib-pair analysis detects elevated Lp(a) levels and large variation of Lp(a) concentration in subjects with familial defective apoB. Y.Y. van der Hoek, A. Lingenhel, H.G. Kraft, J.C. Defesche, J.J.P. Kastelein, G. Utermann. J Clin Invest 1997; 99: 2269-2273. 95. Genetic variant showing a positive interaction with -blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in CAD patients. The Ser447Stop substitution in the lipoprotein lipase gene. B.E. Groenemeijer, M.D. Hallman, P.W.A. Reymer, E. Gagné, J.A. Kuivenhoven, T. Bruin, H. Jansen, K.I. Lie, A.V.G. Bruschke, E. Boerwinkle, M.R. Hayden and J.J.P. Kastelein. Circulation 1997; 95:2628-2635. 96. The identification and significance of a Thr->Pro polymorphism in Kringle IV type 8 of apolipoprotein (a). J. Prins, F.R. Leus, Y.Y. van der Hoek, J.J.P. Kastelein, B.N. Bouma, H.J.M. van Rijn. Tromb & Haemostasis 1997;77:949-954. 97. A single Ser259Arg mutation in the gene for lipoprotein lipase causes chylomicronemia in Moroccans of Berber ancestry. L. Foubert, T. Bruin, J.L. de Gennes, E. Ehrenborg, J. Furioli, J.J.P. Kastelein, P. Benlian, M.R. Hayden. Human Mutation. 1997; 10: 179-185. 98. Lipoprotein(a) is not present in the plasma of patients with some peroxisomal disorders. Y.Y. van der Hoek, R.J.A. Wanders, A.E. van den Ende, H.G. Kraft, J.J.P. Kastelein, M.L. Koschinsky. J Lipid Res 1997; 8: 1612-1619. 99. Effects of gemfibrozil or simvastatin on apolipoprotein-B containing lipoproteins, apolipoproteins-CIII and lipoprotein(a) in familial combined hyperlipidemia. S.J.H. Bredie, H.E. Westerveld, H.C. Knipscheer, T.W.A. de Bruin, J.J.P. Kastelein and A.F.H. Stalenhoef. Neth. J. Med. 1997; 49: 59-67. 100. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue type plasminogen activator, plasminogen activator inhibitor 1 and fibrinogen in hyperlipidaemic patients. M. Kockx, M.M.P. de Maat, H.C. Knipscheer, J.J.P. Kastelein, C. Kluft, H.M.G. Princen, T. Kooistra. Trombosis & Haemostasis 1997; 78: 1167-1172. 101. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. L.A.J. Kluijtmans, J.J.P. Kastelein, J. Lindemans, G.H.J. Boers, S.G. Heil, A.V.G. Bruschke, W.J. Jukema, L.P.W.J. van den Heuvel, F.J.M. Trijbels, G.J.M. Boerma, F.W.A. Verheugt, F. Willems, H.J. Blom. Circulation 1997; 96: 2573-2577. 102. Short report on DNA marker at candidate locus. A novel mutation M-21V in exon 1 of the low density lipoprotein receptor gene causing familial hypercholesterolemia. P. Lombardi, J.C. Defesche, S.W.A. Kamerling, J.J.P. Kastelein, L.M. Havekes. Clin Genet 1997; 51: 430-431. 103. Ethnic variation and in-vivo effects of the -93Promoter variant in the lipoprotein lipase gene. E. Ehrenborg, S.M. Clee, S.N. Pimstone, P.W.A. Reymer, P. Benlian, C.F. Hoogendijk, H.J. Davis, N. Bissada, L. Miao, S.E. Gagné, J. Greenberg, H. Henderson, J.M. Ordovas, E.J. Schaefer. J.J.P. Kastelein, M.J. Kotze and M.R. Hayden. Arterioscler Thromb Vasc Biol.1997; 17: 2672-2679. 104. A common C-to-T substitution at position -480 of the hepatic lipase promotor associated with a lowered lipase activity in coronary artery disease patients. H. Jansen, A.J.M. Verhoeven, L. Weeks, J.J.P. Kastelein, D.J.J. Halley, A. Van den Ouweland, J.W. Jukema, J.C. Seidell, J.C. Birkenhäger. ATVBb 1997;17:2837-43. 105. Is opsporing van familiaire hypercholesterolemie geïndiceerd bij kinderen? H.D. Bakker, A. Wiegman, J.C. Defesche, J.J.P. Kastelein. Ned Tijdschr Geneeskd 1997; 141: 2548-2551. 106. Risk of progression of coronary atherosclerosis is influenced by a common functional variant in the human stromelysin-1 gene promoter. M.P.M. de Maat, J.W. Jukema, S. Ye, A.H. Zwinderman, M. Beekman, J.J.P. Kastelein, A.J. van Boven, A. Bruschke, S.E. Humphries, C. Kluft, A.M. Henney. Conceptuur, 1997;14:37-8. 1998 107. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. J.A. Kuivenhoven, J.W. Jukema, A.H. Zwinderman, P. de Knijff, R. McPherson, A.V.G. Bruschke, K.I. Lie, J.J.P. Kastelein, also on behalf of the REGRESS study group. New Eng J Med 1998; 338: 86-93. 108. The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. J.J.P. Kastelein, B.E. Groenemeijer, M.D. Hallman, H. Henderson, P.W.A. Reymer, S.E. Gagné, H. Jansen, J.C. Seidell, D. Kromhout, J.W. Jukema, A.V.G. Bruschke, E. Boerwinkle, M. Hayden, also on behalf of the Regress Study Group. Clin Genet 1998; 53: 27-33. 109. -445G/A polymorphism of the-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men. Proposed role for an acute-phase reaction pattern of fibrinogen. M.P.M. de Maat, J.J.P. Kastelein, J.W. Jukema, A.H. Zwinderman, H. Jansen, B.E. Groenemeijer, A.V.G. Bruschke, C. Kluft, on behalf of the REGRESS group. ATVB. 1998; 18: 265-271. 110. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolaemia. M.C. Verhaar, R.M.F. Wever, J.J.P. Kastelein, T. van Dam, H.A. Koomans, T.J. Rabelink. Circulation 1998; 97: 237- 111. A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with Familial Hypercholesterolemia. M.E. Wittekoek, S.N. Pimstone, P.W.A. Reymer, L. Feuth, G.J. Botma, J.C. Defesche, M. Prins, M.R. Hayden, J.J.P. Kastelein. Circulation 1998; 97: 729-735. 112. Optimale reductie van cardiovasculair risico: wie verdient behandeling met HMG-CoA reductaseremmers? M. van Dam, J.J. Kastelein. Cardiol 1998;5:143-5 113. Gender-related association between the -93TG/D9N haplotype of the lipoprotein lipase gene and elevated lipid levels in familial combined hyperlipidemia. M.J.V. Hoffer, S.J.H. Bredie, H. Snieder, P.W.A. Reymer, P.N.M. Demacker, L.M. Havekes, D.I. Boomsma, A.F.H. Stalenhoef, R.R. Frants, J.J.P. Kastelein. Atherosclerosis 1998; 138: 91-99. 114. Lipid-free apolipoprotein (apo) A-I is converted into alpha-migrating high density lipoproteins by lipoprotein-depleted plasma of normolipidemic donors and apo A-I-deficient patients but not of Tangier disease patients. A. von Eckardstein, Y. Huang, J.J.P. Kastelein, J. Geisel, J.T. Real, J.A. Kuivenhoven, R. Miccoli, G. Noseda, G. Assmann. Atherosclerosis 1998; 138: 25-34. 115. Ile225Thr loop mutation in the lipoprotein lipase (LPL) gene is a de novo event. H.E. Henderson, S.M. Bijvoet, M.A.M.M. Mannens, T. Bruin, D.W. Erkelens, M.R. Hayden, J.J.P. Kastelein. Am J Med Gen 1998; 78: 313-316. 116. The functional and clinical significance of the MetThr subsitution in kringle IV type 10 of apolipoprotein(a). J. Prins, Y.Y. van der Hoek, T.H. Biesheuvel, F.R. Leus, H.J.M. van Rijn, J.J.P. Kastelein. Thrombosis Research 1998; 90: 125-130. 117. Efficacy and six-month safety of simvastatin 80 mg/day: Results from the Worldwide Simvastatin Expanded Dose Program (WSEDP). L. Ose. J.J.P. Kastelein, R. Scott, E.A. Stein, S. Campodonico, I.D. Escobar, A.C. Tate, L. Corsetti, A. Shahane, Y.B. Mitchel, M. Mercuri for the WSEDP Research Group. Nutr. Metab. Cardiovasc. Dis. 1998; 8: 135-143. 118. Plasma and fibroblasts of Tangier disease patients are disturbed in transferring phospholipids onto apolipoprotein A-I. A. von Eckardstein, A. Chirazi, S. Schuler-Lüttmann, M. Walter, J.J.P. Kastelein, J. Geisel, J.T. Real, R. Miccoli, G. Noseda, G. Höbbel, G. Assmann. J Lipid Res 1998; 39: 987-998. 119. Increased oxidizability of low density lipoproteins in hypothyroidism. Th. Diekman, P.N.M. Demacker, J.J.P. Kastelein, A.F.H. Stalenhoef, W.M. Wiersinga. J Clin Endocrinol Metab. 1998; 83: 1752-1755. 120. Behandeling en preventie van coronaire hartziekten door verlaging van de serumcholesterolconcentratie; derde consensus ‘Cholesterol’. M.L. Simoons en A.F. Casparie, namens de voorbereidingswerkgroep 3e cholesterol consensus. Ned Tijdschr Geneeskd 1998; 38: 2096-2101. 121. Molecular epidemiology of familial hypercholesterolaemia. J.C. Defesche, J.J.P. Kastelein. Lancet 1998; 352: 1643-1644. 122. Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy. S. Rust, M. Walter, H. Funke, A. von Eckardstein, P. Cullen, H.Y. Kroes, R. Hordijk, J. Geisel, J.J.P. Kastelein, H.O.F. Molhuizen, M. Schreiner, A. Mischke, H.W. Hahmann, G. Assmann. Nature Genetics 1998; 20: 96-98. 123. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. B.J. Verhoeff, M.D. Trip, M.H. Prins, J.J.P. Kastelein, P.H. Reitsma. Atherosclerosis 1998; 141: 161-166. 124. Familial hypercholesterolemia: molecular genetics and clinical expression. J.C. Defesche, M.E. Wittekoek, J.J.P. Kastelein. Atherosclerosis XI B. Jacotot, D. Mathé, J.C. Fruchart, editors. 1998, 709-712. 125. Optimal reduction in cardiovascular risk: whom should we treat with HMG-CoA reductase inhibitors. J.J.P. Kastelein. Atherosclerosis XI B. Jacotot, D. Mathé, J.C. Fruchart, editors. 1998, 289-293. 126. Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease. R.F. Franco, M.A. Zago, M.D. Trip, H. ten Cate, A. van den Ende, M.P. Prins, J.J.P. Kastelein, P.H. Reitsma. Brit J Haematol 1998; 102: 1172-1175. 127. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. M. Farnier, and the Cerivastatin Study Group. Am J Cardiol 1998; 82: 47j-51j. 1999 128. Effect of the Stromelysin-1 Promotor on Efficacy of Pravastatin in Coronary Atherosclerosis and Restenosis. M.P.M. de Maat, J.W. Jukema, Shu Ye, A.H. Zwinderman, P.H. Moghadaam, M. Beekman, J.J.P. Kastelein, A.J. van Boven, A.V.G. Bruschke, S.E. Humphries, C. Kluft, A.M. Henney. Am J Cardiol 1999; 83: 852-856. 129. The future of best practice. J.J.P. Kastelein. Atherosclerosis 1999, 143 (Supp. 1) S17-S21. 130. Bringing about best practice in atherosclerosis. J.J.P. Kastelein. Atherosclerosis 1999, 143 (Supp. 1) S1. 131. Nitric oxide production is reduced in patients with chronic renal failure. R. Wever, P. Boer, M. Hijmering, E. Stroes, M. Verhaar, J.J.P. Kastelein, K. Versluis, F. Lagerwerf, H. van Rijn, H. Koomans, T. Rabelink. Arterioscler Thromb Vasc Biol 1999;19:1168-72. 132. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. M.C. Verhaar, M.L.H. Honing, Th. van Dam, M. Zwart, H.A. Koomans, J.J.P. Kastelein, T.J. Rabelink. Cardiovasc. Res. 1999; 42: 752-760. 133. The 20210 G  A mutation in the 3’-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. R.F. Franco, M.D. Trip, H. ten Cate, A. van den Ende, M.H. Prins, J.J.P. Kastelein, P.H. Reitsma. British Journal of Haematology 1999; 104: 50-54. 134. Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins. H.E. Henderson, J.J.P. Kastelein, A.H. Zwinderman, E. Gagne, W.J. Jukema, P.W.A. Reymer, B.E. Groenemeijer, K.I. Lie, A.V.G. Bruschke, M.R. Hayden, H. Jansen. J. Lipid Res. 1999; 40: 735-743. 135. Familial Hypercholesterolemia. Acceptor Splice Site (GC) mutation in intron 7 of the LDL-R gene: alternate RNA editing causes exon 8 skipping or a premature stop codon in exon 8. L. Yu, E. Heere-Ress, B. Boucher, J.C. Defesche, J.J.P. Kastelein, M.A. Lavoie, J. Genest Jr. Atherosclerosis. 1999; 146: 125-131. 136. A common truncation variant of lipoprotein lipase (S447X) confers protection against coronary heart disease: The Framingham Offspring Study. S.E. Gagné, M.G. Larson, S.N. Pimstone, E.J. Schaefer, J.J.P. Kastelein, P.W.F. Wilson, J.M. Ordovas, M.R. Hayden. Clin Genet 1999; 55: 450-454. 137. Mutations in the ABC1 in Tangier disease and familial high-density lipoprotein deficiency. A. Brooks-Wilson, M. Marcil, S.M. Clee, L.H. Zhang, K. Roomp, M.J. van Dam, L. Yu, C. Brewer, J.A. Collins, H.O.F. Molhuizen, O. Loubser, B.F.F. Ouelette, K. Fitchter, K.J.D. Ashbourne-Excoffen, C.W. Sensen, S. Scherer, S. Mott, M. Denis, D. Martindale, J. Frohlich, K. Morgan, B. Koop, S.N. Pimstone, J.J.P. Kastelein, J. Genest Jr., M.R. Hayden. Nature Genetics 1999; 22: 336-345. 138. Opsporing van patienten met Familiaire Hypercholesterolemia in Nederland. M.A.W. Umans-Eckenhausen, J.C. Defesche, R.L.J.M. Scheerder, F. Cliné, J.J.P. Kastelein. Ned Tijdschr Geneeskd 1999; 143: 1157-1161. 139. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. M.C. Verhaar, R.M.F. Wever, J.J.P. Kastelein, D. van Loon, S. Milstien, H.A. Koomans, T.J. Rabelink. Circulation 1999; 100: 335-338. 140. Physical activity modulates the effect of a lipoprotein lipase mutation (D9N) on plasma lipids and lipoproteins. J.M.A. Boer, J.A. Kuivenhoven, E.J.M. Feskens, E.G. Schouten, L.M. Havekes, J.C. Seidell, J.J.P. Kastelein, D. Kromhout. Clin. Genetics. 1999; 56: 158-163. 141. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. M. Marcil, A. Brooks-Wilson, S.M. Clee, K. Roomp, L.-H. Zhang, L. Yu, J.A. Collins, M. van Dam, H.O.F. Molhuizen, O. Loubster, B.F.F. Ouellette, C.W. Sensen, K. Fichter, S. Mott, M. Denis, B. Boucher, S.N. Pimstone, J. Genest Jr, J.J.P. Kastelein. The Lancet 1999; 354: 1341-1346. 142. Activation of the contact system of coagulation does not contribute to the hemostatic imbalance in hypertriglyceridemia. M.C. Minnema, M.E. Wittekoek, N. Schoonenboom, J.J.P. Kastelein, C.E. Hack, H. ten Cate. Arterioscler Thromb Vasc Biol 1999; 19: 2548-2553. 143. Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease. M.E. Wittekoek, E. de Groot, M.H. Prins, M.D. Trip, H.R. Büller, J.J.P. Kastelein. Atherosclerosis. 1999; 146: 271-279. 144. Molecular basis of genetic dyslipidemia. H.O.F. Molhuizen, J.C. Defesche, M.D. Trip, J.J.P. Kastelein. CVR&R 1999; 20: 607 – 619. 145. A frequent mutation in the lipoprotein lipase gene (D9N) deteriorates the biochemical and clinical phenotype of familial hypercholesterolemia. M.E. Wittekoek, E. Moll, S.N. Pimstone, M.D. Trip, P.J. Lansberg, J.C. Defesche, J.J. van Doormaal, M.R. Hayden and J.J.P. Kastelein. Arterioscler Thromb Vasc Biol 1999; 19: 2708-2713. 146. Farmacogenomie en atherosclerose. Genetische variatie in het lipidenmetabolisme. H.O.F. Molhuizen, J.J.P. Kastelein. In: Ziekten maken en breken. Over farmacogenomie. Eds. J.J.E. van Everdingen, A.F. Cohen, G. Feenstra. pp. 55-61. 147. Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women. J.J.P. Kastelein, J.M. Ordovas, M.E. Wittekoek, S.N. Pimstone, P.W.F. Wilson, S.E. Gagné, M.G. Larson, E.J. Schaefer, J.M.A. Boer, Ch. Gerdes, M.R. Hayden. Clin genet. 1999; 56: 297-305. 148. Stoornissen in de vetstofwisseling. Vele oorzaken, fatale gevolgen. J.J.P. Kastelein. Pharm Weekblad 1999; 134; 1659-1664. 149. Analysis of lipoprotein lipase haplotypes reveals association not apparent from analysis of the constituent loci. D.M. Hallman, B.E. Groenemeijer, J.W. Jukema, E. Boerwinkle, J.J.P. Kastelein. Ann Hum Genet 1999; 63: 499-510. 2000 150. Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease. J. Heikens, M.C. Ubbink, H.P.J. van der Pal, P.J.M. Bakker, E. Fliers, T.J. Smilde, J.J.P. Kastelein, M.D. Trip. Cancer 2000; 88: 2116-2121. 151. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. M.R. Hayden, S.M. Clee, A. Brooks-Wilson, J. Genest Jr, A. Attie and J.J.P. Kastelein. Curr Opin Lipidol 2000; 11: 117-122. 152. Molecular genetic testing for Familial Hypercholesterolemia: spectrum of LDL receptor gene mutations in The Netherlands. M.P. Lombardi, E.J.W. Redeker, J.C. Defesche, S.W.A. Kamerling, M.M.A.M. Mannens, L.M. Havekes, J.J.P. Kastelein. Clin Genet 2000; 57: 116-124. 153. Additional risk factors influence excess mortality in heterozygous familial hypercholaemia. E.J.G. Sijbrands, R.G.J. Westendorp, M.P. Lombardi, L.M. Havekes, R.R. Frants, J.J.P. Kastelein, A.H.M. Smelt. Atheroscl 2000;149:421-5. 154. Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia. F.R. Leus, M.E. Wittekoek, J. Prins, J.J.P. Kastelein, H.A.M. Voorbij. Atherosclerosis 2000; 149: 371-377. 155. Mutations in ABC1 in Tangier disease and familial high density lipoprotein deficiency. M. Marcil, A. Brooks-Wilson, J.J.P. Kastelein, M.R. Hayden, J. Genest Jr. Médecine Sciences 2000; 3: 421-430. 156. Phenotypic correction of feline lipoprotein lipase deficiency by adenoviral gene transfer. G. Liu, J.E. Wilson, B.M. McManus, Q.R. Rogers, L. Miao, J.J.P. Kastelein, M.E.S. Lewis, M.R. Hayden. Human Gene Therapy 2000;11:21-32. 157. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. S.M. Clee, N. Bissada, F. Miao, L, Miao, A.D. Marais, H.E. Henderson, P. Steures, J. McManus, B. McManus, R.C. LeBoeuf, J.J.P. Kastelein, M.R. Hayden. J Lipid Res 2000; 41: 521-531. 158. Additional efficacy of milligram-equivalent doses of atorvastatin over simvastatin. M. van Dam, D.C.G. Basart, Ch. Janus, R. Zwertbroek, H.A.M. Spierenburg, H.A. Werner, A.C. Bredero, P.J. Lansberg, C.J. Jonker, M.D. Trip, M.H. Prins, J.J.P. Kastelein. Clin Drug Invest 2000; 19: 327-334. 159. Additional efficacy of milligram-equivalent doses of atorvastatin over simvastatin. M. van Dam, D.C.G. Basart, Ch. Janus, R. Zwertbroek, H.A.M. Spierenburg, H.A. Werner, A.C. Bredero, P.J. Lansberg, C.J. Jonker, M.D. Trip, M.H. Prins, J.J.P. Kastelein. Cardiologie 2000; 7: 173-178. 160. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patient with FH. T. Smilde, F. vd Berkmortel, H. Wollersheim, H. van Langen, J. Kastelein, A.Stalenhoef. EJClinInv 2000;30:473-480. 161. The ILIB Lipid Handbook for Clinical Practice. Blood lipids and coronary heart disease. Second Edition. Authors.: A.M. Gotto, G. Assmann, R. Carmena, J. Davignon, A. Fernandex-Cruz, J.C. Fruchart, J.J.P. Kastelein, R. Paoletti. 162. Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. L. Ose, M.H. Davidson, E.A. Stein, J.J.P. Kastelein, R.S. Scott, D.B. Hunninghake, S. Campodonico, W. Insull, I.D. Escobar, H.G. Schrott, M.E. Stepanavage, M. Wu, A.C. Tate, M.R. Melino, M. Mercuri, Y.B. Mitchel, for the world wide expanded dose simvastatin study group. Clin Cardiol 2000; 23: 39-46. 163. Tailored therapy to fit individual profiles; genetics and coronary arthery disease. J.W. Jukema, J.J.P. Kastelein. In: Atherosclerosis V. The Fifth Saratoga International Conference. Eds.: F. Numano, M.A. Gimbrone Jr. Elseviers publishers, pp. 17-26. 164. Prevalentie van Familiaire Hypercholesterolemie onder volwassenen in vier huisartsenpraktijken hoger dan werd aangenomen. P.J. Lansberg, S. Tuzgöl, M.A. van de Ree, J.C. Defesche, J.J.P. Kastelein. Ned Tijdschr Geneeskd 2000; 144: 1437-1440. 165. Familiaire hypercholesterolemie: cardiovasculaire complicaties op jonge leeftijd te verwachten en te voorkomen. M.D. Trip, P.J. Lansberg, S. de Jongh, J.J.P. Kastelein. Ned Tijdschr Geneeskd 2000; 144: 1425-1428. 166. Comparison of effects of simvastatin versus atorvastatin on high density lipoprotein cholesterol and apolipoprotein A-I levels. J.J.P. Kastelein, J.L. Iscaacsohn, L. Ose, D.B. Hunninghake, J. Frohlic